CTRI/2021/02/031451已完成1 期
Immunogenicity Assessment Extension Study OF Phase 1 PartOf Protocol NCOV 1002
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Subjects has completed the Phase 1 study (NCOV 1002) in treatment arms 3 & 4 (i.e. 2
- •mg vaccine)
- •2. Willing to participate and provide informed consent for the study
排除标准
- •1. Subjects who received another COVID vaccine after administration of last dose of
- •vaccine in NCOV 1002.
- •2. Subjects having history of positive documented COVID-19 infection after completion
- •of study in Phase I part of NCOV 1002
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Focetria TxVaccination for H1N1sw of immunocompromised adults who have undergone solid organ or bone marrow transplantation and of healthy adultsMedDRA version: 12.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-017052-27-DEMedizinische Hochschule Hannover
进行中（未招募）
不适用
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Fluad TxEUCTR2010-022871-78-DEMedizinische Hochschule Hannover
进行中（未招募）
不适用
Etude de phase II évaluant l'immunogénicité et la tolérance d'un vaccin inactivé non adjuvanté contre la grippe A/H1N1v chez la femme enceinte - PREFLUVACGrippe A H1N1MedDRA version: 12.0Level: LLTClassification code 10016797Term: Flu-like symptomsEUCTR2009-016660-36-FRInserm
进行中（未招募）
不适用
Etude de phase II évaluant l'immunogénicité et la tolérance d'un vaccin inactivé non adjuvanté contre la grippe A (H1N1) après transplantation rénale - TRANSFLUVACEUCTR2009-016659-23-FRInserm
已完成
4 期
to evaluate the Immunogenicity and Safety of Typbar-TCV® in AdultsCTRI/2019/10/021823Bharat Biotech International Ltd300